- Poster presentation
Pooled analysis of safety for micafungin
Critical Care volume 12, Article number: P21 (2008)
We characterised the safety of MICA by analysing pooled adverse event (AE) data from 17 clinical studies conducted worldwide. All patients (n = 3,028) received ≥ 1 dose of intravenous MICA; a median daily dose of 100 mg for adults and 1.5 mg/kg for children over a mean duration of 18 and 29 days, respectively.
Median age was 40.5 (range <0.1–92) years, including 296 (9.8%) children (<16 years old) and 387 (12.8%) elderly patients (≥ 65 years old). Common underlying conditions were haematopoietic stem cell or other transplantation (26%), malignancies (21%) and HIV (33%). The most frequently reported MICA-related AEs were nausea (2.8%), vomiting (2.5%), phlebitis (2.5%), hypokalaemia (2.1%), pyrexia (2.1%), diarrhoea (2.0%), and increases in alkaline phosphatase (2.7%), aspartate aminotransferase (2.3%) and alanine aminotransferase (2.0%). In comparative studies, the MICA safety profile was superior to liposomal amphotericin B, and similar to fluconazole and caspofungin (Figure 1).
This large database with more than 3,000 patients demonstrated a favourable clinical safety profile for micafungin.
Kuse ER, et al: Lancet. 2007, 369: 1519-1527. 10.1016/S0140-6736(07)60605-9.
de Wet NT, et al: Aliment Pharmacol Ther. 2005, 21: 899-907. 10.1111/j.1365-2036.2005.02427.x.
van Burik JA, et al: Clin Infect Dis. 2004, 39: 1407-1416. 10.1086/422312.
Pappas PG, et al: Clin Infect Dis. 2007, 45: 883-893. 10.1086/520980.
Rights and permissions
About this article
Cite this article
Cornely, O., Maddison, P. & Ullmann, A. Pooled analysis of safety for micafungin. Crit Care 12 (Suppl 2), P21 (2008). https://doi.org/10.1186/cc6242
- Alkaline Phosphatase
- Fungal Infection
- Safety Profile